Serum Eosinophilic Cationic Protein Fails to Predict Bronchiolitis Severity Independently

Biomarker Discovery and Risk Stratification in Infant Bronchiolitis

Acute bronchiolitis remains a primary driver of pediatric hospitalizations, often presenting with a clinical heterogeneity that complicates early risk assessment [1]. Distinguishing between various wheezing phenotypes in early childhood is notoriously difficult, as underlying etiologies and long-term respiratory outcomes vary significantly among infants [2]. Eosinophil-derived mediators, including eosinophilic cationic protein (a cytotoxic protein released by activated eosinophils that serves as a marker of Type 2 inflammation), are established markers of airway inflammation often used to monitor pediatric asthma and other allergic airway diseases [3, 4]. Despite their utility in chronic airway management, the role of these proteins in the acute setting of viral bronchiolitis remains poorly defined, especially regarding their ability to predict severe outcomes like mechanical ventilation [5, 6]. A new study now evaluates whether measuring these serum levels at presentation can effectively identify infants at the highest risk for clinical deterioration.

Comparative Analysis of Serum ECP in Diagnostic Settings

The researchers conducted a prospective cross-sectional analysis to determine if serum eosinophilic cationic protein (ECP) could serve as a reliable biomarker for acute bronchiolitis. The study enrolled 96 children aged 1 to 24 months with acute bronchiolitis and compared them to 96 age-matched and sex-matched healthy controls. At the time of presentation, the clinical team measured serum ECP levels and routine laboratory parameters to establish a baseline for comparison between the symptomatic and asymptomatic cohorts. By utilizing a matched control group, the authors sought to isolate the specific inflammatory signature of the viral infection from normal physiological variations in early childhood. This is particularly relevant because the infant immune system is in a state of rapid flux, and establishing what constitutes a pathological elevation versus a developmental norm is critical for clinical interpretation.

The results indicated that serum ECP levels did not differ significantly between children with bronchiolitis and healthy controls, suggesting that the protein lacks the sensitivity and specificity required for diagnostic utility in this clinical context. While the researchers performed age-stratified analyses that revealed distinct leukocyte profiles across infancy, reflecting the natural maturation of the immune system, serum ECP concentrations remained comparable between different age groups. This stability across the 1 to 24 month age range suggests that while other white blood cell populations fluctuate as an infant grows, ECP levels do not follow a predictable developmental trajectory that would interfere with its measurement; however, its failure to distinguish between healthy and infected patients limits its role in the initial diagnostic workup for clinicians seeking a definitive infection marker.

Correlation with Systemic Inflammation and Clinical Severity

To understand how serum ECP relates to the broader immune response during acute infection, the researchers utilized Spearman correlation analysis (a statistical method used to measure the strength and direction of the relationship between two continuous variables). This analysis revealed that serum ECP levels demonstrated significant positive correlations with total leukocyte count, as well as with specific leukocyte subpopulations including neutrophils, monocytes, and eosinophils. Beyond these hematological markers, the study found that serum ECP levels also correlated positively with serum glucose levels, which often rise as a result of the metabolic stress response in acutely ill infants. These findings suggest that ECP elevation is not an isolated event but rather a component of a broader, coordinated systemic inflammatory response during the acute phase of bronchiolitis, potentially reflecting the overall magnitude of the host immune activation.

The clinical utility of ECP was further scrutinized by examining its relationship with specific clinical severity indicators, which included oxygen requirement, ICU admission, and mechanical ventilation. Within the cohort of children with bronchiolitis, the researchers observed that significantly higher ECP levels were present in those requiring ICU admission and in children requiring mechanical ventilation. While these associations were statistically significant, the researchers noted that ECP may serve as a marker of a specific inflammatory phenotype (the observable characteristics of an individual's immune response driven by specific biological pathways) rather than a direct causal driver of disease. For the practicing clinician, this suggests that while elevated ECP reflects a more intense inflammatory state associated with severe outcomes, it may function more as a biological indicator of disease intensity than as a primary tool for clinical risk stratification at the bedside.

Tobacco Exposure as a Dominant Predictor of Disease Severity

The study investigated environmental factors that might influence disease progression, specifically focusing on prenatal or passive tobacco smoke exposure. When analyzing the cohort of 96 children with bronchiolitis, the researchers found that significantly higher serum ECP levels were observed in children with prenatal or passive tobacco smoke exposure. This finding suggests that environmental tobacco smoke may exacerbate the eosinophilic inflammatory response in the infant airway, potentially contributing to the more severe clinical presentations observed in these patients. This connection is vital for clinicians to recognize, as it highlights how environmental triggers can shift the biological profile of a viral infection toward a more aggressive inflammatory state.

To determine which factors truly drive clinical outcomes, the researchers performed a multivariable binary logistic regression (a statistical model used to determine the impact of multiple independent variables on a single binary outcome, such as severe versus non-severe disease). This analysis was designed to identify independent predictors of severe bronchiolitis while controlling for confounding factors such as age and comorbidities. In this multivariable analysis adjusting for age and tobacco smoke exposure, serum ECP was not independently associated with severe disease. Instead, tobacco smoke exposure emerged as a strong independent predictor of severe bronchiolitis, carrying more weight in predicting clinical deterioration than the biomarker levels themselves.

These findings clarify the role of ECP in the clinical setting. The researchers concluded that ECP elevation reflects distinct inflammatory phenotypes (specific biological patterns of immune activation) rather than serving as a direct clinical risk stratification tool. For the practicing physician, this indicates that while ECP levels may rise in response to smoke exposure or severe inflammation, they do not provide prognostic information beyond what is already captured by a thorough environmental history. The data reinforce the critical importance of identifying tobacco smoke exposure as a primary risk factor for severe disease in infants presenting with acute bronchiolitis, suggesting that clinical history remains superior to this specific biomarker for predicting which patients will require intensive care.

References

1. Openshaw P, Chiu C, Culley FJ, Johansson C. Protective and Harmful Immunity to RSV Infection. Annual Review of Immunology. 2017. doi:10.1146/annurev-immunol-051116-052206

2. Potter PC. Current guidelines for the management of asthma in young children. Allergy Asthma and Immunology Research. 2009. doi:10.4168/aair.2010.2.1.1

3. Chen X, Tan S, Lu Q, Liu T, Jiang Y. Serum Eosinophil Cationic Protein (ECP) as a Biomarker for Distinguishing Pediatric Allergic Airway Diseases. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27073045

4. Tota M, Łacwik J, Laska J, Sędek Ł, Gomułka K. The Role of Eosinophil-Derived Neurotoxin and Vascular Endothelial Growth Factor in the Pathogenesis of Eosinophilic Asthma. Cells. 2023. doi:10.3390/cells12091326

5. Bedir S, Seçilmiş Y. Association of Serum Eosinophilic Cationic Protein With Disease Severity in Infant Bronchiolitis.. Pediatric emergency care. 2026. doi:10.1097/PEC.0000000000003617

6. Groh M, Rohmer J, Etienne N, et al. French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes. Orphanet Journal of Rare Diseases. 2023. doi:10.1186/s13023-023-02696-4